+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Stimulation latency and comparison of cycling regimens in women using sacral neuromodulation



Stimulation latency and comparison of cycling regimens in women using sacral neuromodulation



Neurourology and Urodynamics 36(2): 486-489



In this two-part study, we sought to define how long sacral neuromodulation users with overactive bladder should trial a new setting before attributing symptoms to that setting. Subsequently, we evaluated patient preferences of variable stimulation regimens. In the initial phase of this prospective pilot study, participants' devices were turned off and later reactivated; time to symptom recurrence and resolution were recorded. In phase two, participants trialed four settings in a masked fashion with random order. After unmasking, participants chose their preferred setting and were followed 1 year. Twelve subjects completed phase one. With the device off, the mean time to symptom recurrence was 11.25 days. Mean time to symptom regression following reactivation was 6.42 days. Combined, the 90th percentile was 15 days for symptoms to reflect the device's new setting. Among 23 women completing part two, the most popular setting at the time of unmasking was a 1-hr on, 2-hr off cycled setting chosen by 7 (30%) participants. According to published estimates of battery longevity, 14 (61%) participants chose a more energy-conserving setting at the time of unmasking. The mean difference in estimated battery longevity between the chosen and baseline regimens was 14.5 months. These gains diminished in the following year with clinical changes in device settings by patients and providers. Sacral neuromodulation patients should allow a 2-week trial before attributing symptoms to a new setting. With additional information, many opt for energy-conserving settings. A 1-hr on, 2-hr off regimen warrants further study. Neurourol. Urodynam. 36:486-489, 2017. © 2016 Wiley Periodicals, Inc.

(PDF emailed within 0-6 h: $19.90)

Accession: 058905822

Download citation: RISBibTeXText

PMID: 26828425

DOI: 10.1002/nau.22962


Related references

Spanish experience in sacral serve stimulation Case register of the Spanish sacral neuromodulation group. European Urology Supplements 2(1): 142, 2003

Neuromodulation for constipation: sacral and transcutaneous stimulation. Best Practice and Research. Clinical Gastroenterology 25(1): 181-191, 2011

How sacral nerve stimulation neuromodulation works. Urologic Clinics of North America 32(1): 11-18, 2005

Sacral neuromodulation stimulation in fecal incontinence. International Urogynecology Journal 21(12): 1565-1568, 2011

Urinary retention in women and sacral neuromodulation. International Urogynecology Journal 21 Suppl 2: S475-S483, 2011

Sacral neuromodulation for women with Fowler's syndrome. European Urology 38(4): 439-443, 2000

Percutaneous tibial nerve stimulation and sacral neuromodulation: an update. Current Urology Reports 16(2): 4, 2016

Safe Simultaneous Use of Sacral Neuromodulation and Vagal Nerve Stimulation. Female Pelvic Medicine and Reconstructive Surgery 22(1): E1-E2, 2016

Sacral nerve stimulation: neuromodulation for voiding dysfunction and pain. Neurotherapeutics 5(1): 107-113, 2008

Sacral nerve stimulation for neuromodulation of the lower urinary tract. Canadian Journal of Urology 19(5): 6480-6484, 2013

Sacral neuromodulation stimulation for IC/PBS, chronic pelvic pain, and sexual dysfunction. International Urogynecology Journal 21(12): 1553-1558, 2011

Sacral neuromodulation and repetitive magnetic stimulation: applications in pediatric surgery. Acta Medica et Biologica 52(2): 43-50, 2004

Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation. International Urogynecology Journal and Pelvic Floor Dysfunction 18(12): 1395-1398, 2007

Comparison between 50 milligrams and 100 clomiphene citrate regimens in normal cycling women undertaking in vitro fertilization and embryo transfer. Journal of In Vitro Fertilization & Embryo Transfer 3(3): 155-156, 1986

Pregnancy in women with Fowler's syndrome treated with sacral neuromodulation. International Urogynecology Journal 24(7): 1201-1204, 2014